Current use of bisphosphonates in oncology

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3890-3899

  Body, J J ^a   Bartl, R ^a   Burckhardt, P ^a   Delmas, P D ^a   Diel, I J ^a   Fleisch, H ^a   Kanis, J A ^a   Kyle, R A ^a   Mundy, G R ^a   Paterson, A H G ^a   Rubens, R D ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID;

BONE METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0032434254     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3890     Document Type: Review

References (68)

1. Fleisch H: Bisphosphonates in Bone Disease - From the Laboratory to the Patient (ed 3). New York, NY, The Parthenon Publishing Group, 1997
2. Sato M, Grasser W, Endo N, et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105, 1991
3. Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 96:2277-2283, 1995
4. Vitté C, Fleisch H, Guenther HL: Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333, 1996
5. Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487, 1995
6. Body JJ, Delmas PD: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcaemia. J Clin Endocrinol Metab 74:471-475, 1992
7. Dumon JC, Wantier H, Mathieu F, et al: Technical and clinical validation of a new immunoradiometric assay for human osteocalcin. Eur J Endocrinol 135:231-237, 1996
8. Grill V, Ho P, Body JJ, et al: Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73:1309-1315, 1991
9. Body JJ: Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol 4:624-631, 1992
10. Percival RC, Yates AJP, Gray RES, et al: Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J 289:287, 1984
11. Ralston SH: Medical management of hypercalcaemia. Br J Clin Pharmacol 34:11-20, 1992
12. Singer FR, Ritch PS, Lad TE, et al: Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 151:471-476, 1991
13. Rotstein S, Glas U, Eriksson M, et al: Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - A prospective randomised placebo-controlled multicentre study. Eur J Cancer 28A:890-893, 1992
14. Bonjour JP, Philippe J, Guelpa G, et al: Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9:123-130, 1988
15. O'Rourke NP, McCloskey EV, Vasikaran S, et al: Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 67:560-563, 1993
16. Thiébaud D, Jaeger J, Jacquet AF, et al: Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrPB. J Clin Oncol 6:762-768, 1988
17. Body JJ, Dumon JC: Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Dose-response relationship and influence of the tumour type. Ann Oncol 5:359-363, 1994
18. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 341:1611-1613, 1993
19. Wall J, Ratcliffe WA, Howell A, et al: Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br J Cancer 70:169-172, 1994
20. Dodwell DJ, Abbas SK, Morton AR, et al: Parathyroid hormonerelated protein (50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. Eur J Cancer 27:1629-1633, 1991
21. Purohit OP, Radstone CR, Anthony C, et al: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72:1289-1293, 1995
22. Pecherstorfer M, Herrmann Z, Body JJ, et al: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276, 1996
23. Ralston SH, Thiébaud D, Herrmann Z, et al: Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 75:295-300, 1997
24. Mundy GR: Mechanisms of bone metastasis. Cancer 80:1546-1556, 1997
25. Vargas SJ, Gillespie MT, Powell GJ, et al: Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridation. J Bone Miner Res 7:971-979, 1992
26. Siwek B, Lacroix M, de Pollak C, et al: Secretory products of breast cancer cells affect human osteoblastic cells: Partial characterization of active factors. J Bone Miner Res 12:552-560, 1997
27. Guise TA, Mundy GR: Breast cancer and bone. Curr Opin Endocrinol 2:548-555, 1995.
28. Cullen KJ, Yee D, Sly WS, et al: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48-53, 1990
29. O'Rourke N, McCloskey E, Houghton F, et al: Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13:929-934, 1995
30. Robertson AG, Reed NS, Ralston SH: Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study. J Clin Oncol 13:2427-2430, 1995
31. Martoni A, Guaraldi M, Camera P, et al: Controlled clinical study on the use of dichloromethylene disphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97-110, 1991
32. Neri B, Gemelli MT, Sambataro S, et al: Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs 3:87-90, 1992
33. Ernst DS, Mac Donald RN, Paterson AHG, et al: A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Symptom Manage 7:4-11, 1992
34. Coleman RE, Woll PJ, Miles M, et al: Treatment of bone metastases from breast cancer with (3-amino-1 -hydroxypropylidene)-1, 1-bisphosphonate (APD). Br J Cancer 58:621-625, 1988
35. Thiébaud D, Leyvraz S, von Fliedner V, et al: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37-41. 1991
36. Glover D, Lipton A, Keller A, et al: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949-2955, 1994
37. Tyrrell CJ, on behalf of the Aredia Multinational Cooperative Group: Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Ann Oncol 5:S37-S40, 1994 (suppl 7)
38. Purohit OP, Anthony C, Radstone CR, et al: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558, 1996
39. Cascinu S, Casadei V, Del Ferro E, et al: Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. J Support Care Cancer 4:31-33, 1996
40. Vinholes J, Purohit OP, Eastell R, et al: Double-blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc Am Soc Clin Oncol 15:528, 1996 (abstr)
41. Body JJ, Coleman RE, Piccart M: Use of bisphosphonates in cancer patients. Cancer Treat Rev 22:265-287, 1996
42. Ernst DS, Brasher P, Hagen N, et al: A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13:319-326, 1997
43. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791, 1996
44. Belch AR, Bergsagel DE, Wilson K, et al: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9:1397-1402, 1991
45. Paterson AHG, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
46. Rizzoli R, Forni M, Schaad MA, et al: Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 18:531-537, 1996
47. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
48. Conte PF, Latreille J, Mauriac L, et al: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. J Clin Oncol 14:2552-2559, 1996
49. Theriault RL, Lipton A, Leff R, et al: Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (Aredia®) infusion. Proc Am Soc Clin Oncol 15:122, 1996 (abstr 152)
50. Richards MA, Braysher S, Gregory WM, et al: Advanced breast cancer: Use of resources and cost implications. Br J Cancer 67:856-860, 1993
51. Biermann WA, Cantor RI, Fellin FM, et al: An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone 12:37-42, 1991 (suppl 1)
52. van der Pluijm G, Vloedgraven H, van Beek E, et al: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705, 1996
53. Boissier S, Magnetto S, Frappait L, et al: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894, 1997
54. Yoneda T, Sasaki A, Mundy GR: Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32:73-84, 1994
55. Yoneda T, Sasaki A, Dunstan C, et al: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99:2509-2517, 1997
56. Kanis JA, Powles T, Paterson AHG, et al: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667, 1996
57. Diel U, Solomayer EF, Goenner R, et al: Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. Proc Am Soc Clin Oncol 16:130, 1997 (abstr 461)
58. Delmas PD, Balena R, Confraveux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind placebo-controlled study. J Clin Oncol 15:955-962, 1997
59. Fleisch H: New bisphosphonates in osteoporosis. Osteoporosis Int 2:S15-22, 1993
60. 2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163-168, 1982
61. 2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8:23-30, 1990
62. Heim ME, Clemens MR, Queisser W, et al: Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment - A multicenter study. Onkologie 18:439-448, 1995
63. Lahtinen R, Laakso M, Palva I, et al: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052, 1992
64. McCloskey EV, MacLennan ICM, Drayson M, et al: Effect of clodronate on skeletal morbidity in myelomatosis. Br J Hematol 100:317-325, 1998
65. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996
66. Laakso M, Lahtinen R, Virkkunen P, et al: Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 87:725-729, 1994
67. Pecherstorfer M, Ludwig H, Schlosser K, et al: Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 11:587-593, 1996
68. Green JR, Müller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-750, 1994